This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Holidays Came Early This Year for OncoMed and EnteroMedic

NEW YORK (TheStreet) -- It was Two-For-Tuesday in health care this week as EnteroMedics (ETRM) and OncoMed Pharmaceuticals (OMED) soared. At the peak, OncoMed generated all-time highs, reaching above 120% gains before closing with a gain of 98%. EnteroMedics closed right at the highs of the day, up an impressive 63%.

EnteroMedic investors quickly reversed their skepticism after less-than-stellar third-quarter earnings reported in October upon favorable data from its Maestro system obesity study.

Can investors capture greater gains or is now the time to ring the register?

EnteroMedic is an 11-year-old medical device development company that hasn't generated revenue, much less a profit. In October, the company reported the Maestro device demonstrated benefits in three studies. That news, not totally unlike Tuesday's press release, also rocketed shares over 30%.

Maestro system is a device implanted into obese patients that stimulates the vegus nerve between the esophagus and the stomach, lowering hunger sensations. The system is already approved in Europe and Australia and awaits approval in the U.S. A target market is patients with type II diabetes.

Considering the market's currently available and cautiously optimistic outlook for Food and Drug Administration approval, EnteroMedic appears to be a strong buy into a dip. Delivering a favorable study is one thing but it isn't a substitute for revenue and profits.

The likely market reaction is within a few days the stock will settle lower, setting up a more favorable buying opportunity.

ETRM Shares Outstanding Chart

For EnteroMedic, however, option trading volume is so light that the lack of liquidity makes the bid/ask spread too wide for all but the most aggressive type of trades. Chasing the price higher doesn't appear to offer a favorable risk-reward because of dilution fear. The chart above demonstrates a six-fold increase in shares outstanding during the past two years while the annual cash burn rate is near the amount of cash on hand. In the last quarter's conference, the company reported a burn rate of $14.1 million for the first nine months ending Sept. 30.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs